Age, gender, synchronous or metachronous metastases, preoperative laparotomy or laparoscopy, PCI ≥ 20, TN-stage, primary tumour location, mucinous tumors, grade of differentiation, and the presence of KRAS or BRAF mutations were also analyzed but none was significantly associated with lead time. The gene discussed is KRAS; the disease is neoplasm.